Payment overview · 2025
General Payments
$577.33
29 reported records · 14 companies
Healthcare provider profile · identity verified
Albert Carl Winfield, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DANVILLE, VA · NPI 1679588461
Verified facts
What the public records show
CMS Open Payments records show Albert Carl Winfield, M.D. received $577.33 in general payments during 2025 across 29 reported records.
Novo Nordisk Inc accounted for 12.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Mounjaro, Ozempic, Rexulti, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.78 | 12.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $69.12 | 12.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.65 | 9.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.12 | 9.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.89 | 9.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.42 | 8.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.70 | 7.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.13 | 6.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.88 | 5.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.50 | 5.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.91 | 4.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.67 | 4.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.18 | 3.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.38 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $577.33 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $82.03 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $69.12 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.89 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.89 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.16 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.16 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.70 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.95 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.88 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.50 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $28.43 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.62 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 92 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
92 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
130 | 24 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 701 | 191 |
| Metformin Hcl | Metformin Hcl | 320 | 98 |
| Losartan Potassium | Losartan Potassium | 294 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 284 | 86 |
| Omeprazole | Omeprazole | 280 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 277 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 228 | 57 |
| Gabapentin | Gabapentin | 198 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 195 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 39 |
| Alprazolam | Alprazolam | 161 | 23 |
| Montelukast Sodium | Montelukast Sodium | 157 | 33 |
| Simvastatin | Simvastatin | 153 | 39 |
| Lisinopril | Lisinopril | 146 | 42 |
| Trulicity | Dulaglutide | 130 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 112 | 27 |
| Trazodone Hcl | Trazodone Hcl | 112 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 36 |
| Lorazepam | Lorazepam | 100 | 20 |
| Buspirone Hcl | Buspirone Hcl | 99 | 21 |
| Furosemide | Furosemide | 99 | 35 |
| Meloxicam | Meloxicam | 99 | 20 |
| Potassium Chloride | Potassium Chloride | 99 | 31 |
| Mounjaro | Tirzepatide | 92 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 23 |
| Carvedilol | Carvedilol | 84 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 25 |
| Januvia | Sitagliptin Phosphate | 78 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 16 |
| Clonidine Hcl | Clonidine Hcl | 64 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 29 |
| Allopurinol | Allopurinol | 60 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 15 |
| Eliquis | Apixaban | 52 | 14 |
| Glimepiride | Glimepiride | 52 | 16 |
| Donepezil Hcl | Donepezil Hcl | 51 | suppressed |
| Atenolol | Atenolol | 49 | 14 |
| Linzess | Linaclotide | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 49 | 13 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 47 | suppressed |
| Famotidine | Famotidine | 47 | 12 |
| Tramadol Hcl | Tramadol Hcl | 47 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | 20 |
| Ozempic | Semaglutide | 45 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 12 |
| Celecoxib | Celecoxib | 41 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 39 | 15 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Rexulti | Brexpiprazole | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 13 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Prednisone | Prednisone | 35 | 21 |
| Repaglinide | Repaglinide | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | 11 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Valsartan | Valsartan | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Niacin Er | Niacin | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Acyclovir | Acyclovir | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 12 |
| Clarithromycin | Clarithromycin | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $577.33 · 29 records | Novo Nordisk Inc | BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, FREESTYLE LIBRE 3, HETLIOZ, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error